N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof

US12116356B2 · kind B2 · utility

Assignee

• Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · CN

Inventors

• Yinsheng Zhang · Lianyungang, CN
• Wangwei Ao · Lianyungang, CN
• Yuan Li · Shandong, CN
• Hui Wang · Lo Wu, CN
• Hangzhou Shen · Lianyungang, CN
• Jie Ni · Beijing, CN
• Huan Zhang · Shanghai, CN
• Jie Wu · Freeport, US
• Li Zhang · New Milford, US
• Kai Cao · Lianyungang, CN
• Peng-Cheng Lu · Timonium, US
• Xushi Liu · Lianyungang, CN
• Jie Wang · Lake Bluff, US
• Tianxiao Zhao · Lianyungang, CN
• Xingfeng Ge · Nanjing, CN
• Dandan Lu · Lianyungang, CN
• Shuo Chen · Beijing, CN
• Xueqin Ma · Lianyungang, CN
• Wei Shi · 安丰镇, CN
• Xiaojin Wang · Lianyungang, CN
• Hongjiang Xu · Lianyungang, CN

Key dates

• Filing date: Feb 6, 2023
• Grant date: Oct 15, 2024
• Expiry date: Apr 23, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D409/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a medical use thereof. The medical use comprises the use in treating diseases benefiting from the capsid protein assembly inhibitor, and in particular, diseases caused by hepatitis B virus infection.